The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by KBC Group NV

KBC Group NV boosted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 5.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 258,460 shares of the medical device company’s stock after buying an additional 12,435 shares during the period. KBC Group NV’s holdings in Cooper Companies were worth $28,519,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of COO. Victory Capital Management Inc. raised its position in Cooper Companies by 23.0% in the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after acquiring an additional 737,726 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Cooper Companies by 1.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 443,863 shares of the medical device company’s stock worth $48,976,000 after buying an additional 6,489 shares in the last quarter. GSA Capital Partners LLP grew its position in Cooper Companies by 150.6% during the third quarter. GSA Capital Partners LLP now owns 6,993 shares of the medical device company’s stock worth $772,000 after buying an additional 4,202 shares during the period. Venturi Wealth Management LLC increased its holdings in Cooper Companies by 40.4% in the third quarter. Venturi Wealth Management LLC now owns 4,699 shares of the medical device company’s stock valued at $518,000 after buying an additional 1,351 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Cooper Companies during the 3rd quarter worth approximately $318,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on COO. Stifel Nicolaus reaffirmed a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. StockNews.com upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Thursday. Morgan Stanley lifted their target price on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 10th. Piper Sandler increased their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Finally, Wells Fargo & Company lifted their price objective on Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

Cooper Companies Trading Down 0.2 %

Shares of COO opened at $99.63 on Friday. The Cooper Companies, Inc. has a fifty-two week low of $82.21 and a fifty-two week high of $112.38. The company has a market capitalization of $19.84 billion, a PE ratio of 55.50, a price-to-earnings-growth ratio of 2.20 and a beta of 0.99. The stock has a fifty day moving average of $106.83 and a two-hundred day moving average of $97.93. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $997.30 million. During the same period in the prior year, the firm posted $0.84 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

Insider Transactions at Cooper Companies

In other news, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $105.90, for a total value of $2,625,049.20. Following the transaction, the chief financial officer now directly owns 6,614 shares in the company, valued at $700,422.60. This trade represents a 78.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Agostino Ricupati sold 1,601 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares of the company’s stock, valued at $520,488.54. The trade was a 24.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock worth $27,637,427 in the last three months. Company insiders own 2.00% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.